Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study.

ABSTRACT:

Aims

Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonatal opioid withdrawal syndrome (NOWS). It is unknown whether epigenetic variation in OPRM1 exists within placental tissue in women with OUD and whether it is associated with NOWS outcomes. In this pilot study, the authors aimed to 1) examine the association between placental OPRM1 DNA methylation levels and NOWS outcomes, and 2) compare OPRM1 methylation levels in opioid-exposed versus non-exposed control placentas.

Methods

Placental tissue was collected from eligible opioid (n = 64) and control (n = 29) women after delivery. Placenta

SUBMITTER: Wachman EM 

PROVIDER: S-EPMC7985727 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature